Beat on Revs and Profit, but stock down 4%. Why?
After the initial, very short pop, SAVE is now down $2.00 (over 4%)
I guess the revenue per seat - mile ratio which dropped must be the problem.
This stock does not seem ready to head to $60, more like $40
I'm long a few hundred shares, maybe will buy more if it gets down to the 40 range.
In today's announcement, the company authorized a new $1B buy back plan for the next 18 months.
The current market cap for URI is only 5.2 Billion.
Does this mean the company will buy back 20% of existing shares in the next year and a half?
Will EPS go up by 20%?
Today's presentation said the data showed that plasma levels of intact parathyroid hormone (iPTH) continued to fall as serum levels of 25-hydroxyvitamin D (25D) rose above 30 ng/mL, a level considered sufficient for CKD patients in published clinical practice guidelines. These data suggest that patients with stage 3 or 4 CKD require higher levels of serum 25D than previously thought in order to control elevated iPTH.
It seems to me that this is important to Opko because Rayaldee raises this serum level. I didn't see any commentary on this presentation. I hope this isn't a step backwards in the upcoming product launch, but it seems to me that this is another indication of how much the new Rayaldee is needed.
The board of directors are eventually responsible for this mess.
Belkin, in you example, I think you made a mistake. When the option expires, if the price is below $8, you won't buy the stock at $8.00, you would let the option expire. Why would you buy the stock at $8, when you could buy it cheaper on the open market?
That's the thing about Call options. if they expire out of the money, they are worthless.
This company is solidly profitable. They have no debt, good cash flow, and a PEG ratio less than one.
I think it's a great fit for Opko. I like the deal, so I bought some $BRLI today (on top of an already heavy $OPK holding)
I think this Seeking Alpha article explains it.
Terry is the chump, I mean champ.
Who else has turned a $40 per share company into two dollars in such a short time?
Though Radware (NASDAQ:RDWR) beat Q4 estimates, it guided on its CC for Q1 revenue of $56M-$58M and EPS of $0.20-$0.23, mostly below a consensus of $58.1M and $0.23.
Hey, Phil Rykhoek, what do you say? Step up and prove to shareholders you know this company is worth buying here. What about the other company officers? I don't see any insider buying yet.
it's sinking like a torpedoed Swift boat.